Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say
Market Outlook With the stock now trading well above $150, investors are debating how much further PRAX could rise. If ulixacaltamide wins approval, analysts believe it could capture a sizable ET market. However, success in neurology trials can be binary – failures or setbacks could send the stock sharply down. Looking ahead, Praxis expects more data by late 2025/early 2026 (e.g. vormatrigine POWER1 topline, PRAX-562 EMBOLD readout nasdaq.com neurologylive.com). Management’s guidance (via press releases and presentations) has focused on these milestones rather than concrete revenue forecasts, which is typical for clinical-stage biotechs nasdaq.com. In the near term, analysts will scrutinize